D. Boral Capital Reiterates Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $31.00 target price on the stock.

NRXP has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $19.00 target price on shares of NRx Pharmaceuticals in a research note on Thursday, March 20th. Ascendiant Capital Markets lifted their price objective on NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd.

NRx Pharmaceuticals Stock Performance

Shares of NRXP opened at $1.94 on Monday. The stock has a 50 day moving average price of $2.50 and a 200 day moving average price of $2.05. The stock has a market capitalization of $32.82 million, a price-to-earnings ratio of -0.91 and a beta of 1.22. NRx Pharmaceuticals has a one year low of $1.10 and a one year high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its earnings results on Friday, March 14th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). On average, analysts predict that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Sassicaia Capital Advisers LLC purchased a new stake in shares of NRx Pharmaceuticals during the 4th quarter valued at approximately $33,000. Townsquare Capital LLC purchased a new stake in NRx Pharmaceuticals in the third quarter valued at $25,000. Squarepoint Ops LLC purchased a new stake in NRx Pharmaceuticals in the fourth quarter valued at $56,000. Millennium Management LLC acquired a new position in shares of NRx Pharmaceuticals in the 4th quarter valued at $61,000. Finally, Anson Funds Management LP grew its holdings in shares of NRx Pharmaceuticals by 30.3% during the 4th quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock worth $408,000 after purchasing an additional 43,135 shares during the period. 4.27% of the stock is currently owned by institutional investors and hedge funds.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.